Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BLI-489 · 4 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | BLI-489 |
| 2 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| BLI-489 | DRUG | - |
| placebo | DRUG | - |
| BLI-489/Piperacillin | DRUG | - |
| Piperacillin | DRUG | - |
Inclusion Criteria: * Men or women of non-childbearing potential (WONCBP) aged 18 to 50 years inclusive at screening; * Body mass index (BMI) in the range of 18 to 32 kg/m2 and body weight ≥50 kg.; * Healthy as determined by the investigator on the basis of screening evaluations; * Calculated creat...
BLI-489 is an investigational small molecule being studied in healthy subjects, including healthy Japanese male subjects. It is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics, both alone and in combination with piperacillin. It is not approved for any disease indication.
BLI-489 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE on the New York Stock Exchange. The company is conducting Phase 1 clinical trials of this investigational small molecule in healthy volunteers.
BLI-489 is in Phase 1 clinical development. All four clinical trials listed for the drug are Phase 1 studies and have been completed. The drug remains investigational and has not been approved by regulatory authorities.
BLI-489 has been studied in four completed Phase 1 trials: NCT00820404 and NCT00854009 evaluated single doses in healthy subjects and healthy Japanese male subjects, respectively; NCT00894439 evaluated BLI-489 with piperacillin; and NCT00909688 evaluated multiple doses. All trials are completed.
No, BLI-489 is not the same as piperacillin. BLI-489 is an investigational small molecule being studied alone and in combination with piperacillin in a Phase 1 clinical trial (NCT00894439) to evaluate the safety and tolerability of the combination in healthy subjects.